ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action
R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Impact of PASTEUR: 9.9m lives saved, ROI of 125:1
Draft EMA antibacterial guidance: Analysis
Developing antibiotics for children: There are no easy answers
NIAID workshop: What is a robust PK-PD package?
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Draft FDA guidance on anti-infectives for children: It’s (mostly) all about PK and safety
Lancet: 10-20-30 targets to address AMR by 2030
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet